Medicine & Life Sciences
Acute Myeloid Leukemia
57%
Adoptive Immunotherapy
10%
Allogeneic Cells
87%
Allografts
12%
Antigens
11%
Aplastic Anaemia
11%
Autografts
8%
Autologous Transplantation
23%
B-Cell Chronic Lymphocytic Leukemia
15%
B-Lymphocytes
12%
Blood Cells
39%
Blood Component Removal
12%
Blood Platelets
9%
Bone Marrow
76%
Bone Marrow Cells
8%
Bone Marrow Transplantation
39%
Breast Neoplasms
21%
Busulfan
37%
Carmustine
10%
Cell Line
9%
Cell Transplantation
76%
Cell- and Tissue-Based Therapy
26%
Chimeric Antigen Receptors
39%
Clinical Trials
11%
Clofarabine
8%
Confidence Intervals
13%
Cyclophosphamide
38%
Cytarabine
11%
Cytogenetics
19%
Cytokines
8%
Cytomegalovirus
11%
Cytotoxic T-Lymphocytes
9%
Dendritic Cells
9%
Disease-Free Survival
9%
Drug Therapy
40%
Etoposide
8%
Fetal Blood
42%
Filgrastim
10%
fludarabine
33%
GATA2 Deficiency
10%
Graft vs Host Disease
79%
Granulocyte Colony-Stimulating Factor
21%
Haploidentical Transplantation
8%
Hematologic Neoplasms
27%
Hematopoiesis
10%
Hematopoietic Stem Cell Mobilization
9%
Hematopoietic Stem Cell Transplantation
85%
Hematopoietic Stem Cells
34%
HLA Antigens
11%
Hodgkin Disease
15%
Homologous Transplantation
45%
Imatinib Mesylate
20%
Immunotherapy
18%
In Vitro Techniques
9%
Incidence
12%
Lenalidomide
8%
Leukemia
46%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
45%
Leukemia, Myeloid, Chronic Phase
9%
Lymphocytes
12%
Lymphoma
19%
Lymphoma, Large B-Cell, Diffuse
9%
Mantle-Cell Lymphoma
8%
Melphalan
25%
Mesenchymal Stem Cells
15%
Mortality
23%
Multiple Myeloma
46%
Myelodysplastic Syndromes
26%
Myeloid Cells
9%
Myeloid Leukemia
10%
Natural Killer Cells
18%
Neoplasms
36%
Non-Hodgkin's Lymphoma
13%
Peripheral Blood Stem Cell Transplantation
9%
Peripheral Blood Stem Cells
20%
Philadelphia Chromosome
13%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
30%
Primary Myelofibrosis
12%
Progression-Free Survival
22%
Protein-Tyrosine Kinases
13%
Recurrence
36%
Residual Neoplasm
9%
Rituximab
12%
Safety
10%
Siblings
14%
Stem Cell Factor
13%
Stem Cell Transplantation
91%
Stem Cells
62%
Survival
49%
T-Lymphocytes
51%
Tacrolimus
10%
Therapeutics
35%
Thiotepa
8%
Tissue Donors
56%
Transplant Recipients
16%
Transplantation
64%
Transplants
100%
Unrelated Donors
40%
Whole-Body Irradiation
11%